We are a pioneering biotech with world-class expertise to combat anti-microbial resistance and make a profound difference to humanity.
Click through to any subsequent page to learn more:
Micreos is a clinical-stage pharmaceutical biotech developing medicinal solutions that selectively kill only harmful bacteria while preserving the rest of the health-enhancing microbiome.
Our vision is to positively impact patient care while helping global health care systems to address impending anti-microbial resistance (AMR) concerns.
Our unique capability in modular engineering to optimize enzyme therapeutics means that we have already developed four endolysin-based investigational antimicrobials.
These antimicrobials are focused on the detrimental impact of Staphylococcus aureus (S. aureus) in oncology, dermatology, wound-care and bloodstream infections.
Our team is forging ahead, partnering across medicine, to realize the shared goal of better solutions to combat harmful bacteria in an era of antimicrobial resistance.
To do this, we are focused on the challenges facing modern medicine in the 21st century by selecting and engineering biological alternatives to current antibiotics, which are increasingly powerless to combat bacterial infections.
Currently our investigational treatments are being evaluated in four therapeutic areas where burgeoning antibiotic resistance, or concerns about it, leave patients with increasingly limited options:
The past, present and future of Micreos is the result of the talent and integrity of outstanding individuals at every level of the business. Here we showcase the senior team at Micreos, to give an insight into our highly driven team:
29+ years of Pharma, Med-Tech & Diagnostic experience spanning the entire value-chain from drug discovery & development to manufacturing to commercial leadership in large, global healthcare organizations.
World-renowned endolysin researcher and ETH University lecturer.
30+ years of diverse experience in drug development, pharmaceutical value, access & pricing, as well as a renowned expert on health economic outcomes research.
MD with deep expertise in microbiome and biotech development.
20+ years of pharma experience in global, regional and affiliate roles in a large pharmaceutical company.
Successfully built the Arena Pharma international HR function and managed the subsequent transition to Pfizer post-acquisition.
We are a pioneering biotech with world-class expertise to combat anti-microbial resistance and make a profound difference to humanity.
From discovery to launch: transforming the treatment of chronic and acute bacterial infections.
*Data from a phase I/II study in patients with AD (n=39; 13 placebo and 26 active treatment) shows that XZ.700 in concentrations up to 100 ug/g is safe and well tolerated for twice daily administration for up to 14 days to patients with mild to moderate AD.
We welcome collaboration with partners who share our ambition to address the impact of bacterial infection on chronic and acute illness.
Please contact Natalie Samuel: